ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.06 Billion KRW | -32.15% |
| 2022 | 1.57 Billion KRW | 50.13% |
| 2021 | 1.04 Billion KRW | 128.19% |
| 2020 | 459.66 Million KRW | -47.86% |
| 2019 | 881.57 Million KRW | 85.29% |
| 2018 | 475.78 Million KRW | 120.12% |
| 2017 | 216.14 Million KRW | 10.81% |
| 2016 | 195.06 Million KRW | 0.0% |
| 2015 | - KRW | -100.0% |
| 2014 | 1.00 KRW | 0.0% |
| 2013 | 1.00 KRW | 0.0% |
| 2012 | 1.00 KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 321.46 Million KRW | 28.97% |
| 2024 Q1 | 249.24 Million KRW | -76.67% |
| 2023 FY | 1.06 Billion KRW | -32.15% |
| 2023 Q4 | 1.06 Billion KRW | -29.15% |
| 2023 Q1 | 1.86 Billion KRW | 18.27% |
| 2023 Q3 | 1.5 Billion KRW | -7.75% |
| 2023 Q2 | 1.63 Billion KRW | -12.23% |
| 2022 Q4 | 1.57 Billion KRW | -22.05% |
| 2022 Q2 | 2.17 Billion KRW | 17.28% |
| 2022 FY | 1.57 Billion KRW | 50.13% |
| 2022 Q1 | 1.85 Billion KRW | 76.58% |
| 2022 Q3 | 2.02 Billion KRW | -7.0% |
| 2021 Q4 | 1.04 Billion KRW | 10.75% |
| 2021 FY | 1.04 Billion KRW | 128.19% |
| 2021 Q2 | 991.54 Million KRW | 97.04% |
| 2021 Q3 | 947.11 Million KRW | -4.48% |
| 2021 Q1 | 503.22 Million KRW | 9.48% |
| 2020 Q4 | 459.66 Million KRW | -17.5% |
| 2020 Q3 | 557.16 Million KRW | -63.57% |
| 2020 Q1 | 884.73 Million KRW | 0.36% |
| 2020 Q2 | 1.52 Billion KRW | 72.86% |
| 2020 FY | 459.66 Million KRW | -47.86% |
| 2019 Q2 | 857.99 Million KRW | 141.99% |
| 2019 Q3 | 1.07 Billion KRW | 24.87% |
| 2019 FY | 881.57 Million KRW | 85.29% |
| 2019 Q1 | 354.56 Million KRW | -25.48% |
| 2019 Q4 | 881.57 Million KRW | -17.71% |
| 2018 Q1 | 453.71 Million KRW | 109.91% |
| 2018 Q4 | 475.78 Million KRW | -19.24% |
| 2018 FY | 475.78 Million KRW | 120.12% |
| 2018 Q2 | 147.81 Million KRW | -67.42% |
| 2018 Q3 | 589.11 Million KRW | 298.55% |
| 2017 Q1 | 173.88 Million KRW | -10.86% |
| 2017 FY | 216.14 Million KRW | 10.81% |
| 2017 Q3 | 276.08 Million KRW | 77.88% |
| 2017 Q2 | 155.21 Million KRW | -10.74% |
| 2017 Q4 | 216.14 Million KRW | -21.71% |
| 2016 Q2 | 393.2 Million KRW | 0.0% |
| 2016 Q3 | 196.98 Million KRW | -49.9% |
| 2016 Q4 | 195.06 Million KRW | -0.97% |
| 2016 FY | 195.06 Million KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2015 FY | - KRW | -100.0% |
| 2015 Q2 | 1.00 KRW | 0.0% |
| 2015 Q1 | - KRW | -100.0% |
| 2015 Q3 | - KRW | -100.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2014 Q4 | 1.00 KRW | 0.0% |
| 2014 FY | 1.00 KRW | 0.0% |
| 2014 Q2 | 177.79 Million KRW | 0.0% |
| 2014 Q1 | - KRW | -100.0% |
| 2013 Q3 | 1.00 KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q4 | 1.00 KRW | 0.0% |
| 2013 FY | 1.00 KRW | 0.0% |
| 2012 FY | 1.00 KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Co., Ltd. | 11.42 Billion KRW | 90.646% |
| iNtRON Biotechnology, Inc. | 1.01 Billion KRW | -5.663% |
| BINEX Co., Ltd. | 28.26 Billion KRW | 96.22% |
| Bioneer Corporation | 41.35 Billion KRW | 97.417% |
| Anterogen.Co.,Ltd. | 1.91 Billion KRW | 44.08% |
| MEDIPOST Co., Ltd. | 14.51 Billion KRW | 92.641% |
| CrystalGenomics, Inc. | 1.55 Billion USD | 31.286% |
| Helixmith Co., Ltd | 914.11 Million KRW | -16.874% |
| Chabiotech Co.,Ltd. | 34.11 Billion KRW | 96.869% |
| Medy-Tox Inc. | 59.61 Billion KRW | 98.208% |
| Peptron, Inc. | 172.18 Million KRW | -520.463% |
| Amicogen, Inc. | 46.83 Billion KRW | 97.719% |
| Genexine, Inc. | 3.8 Billion KRW | 71.936% |
| HLB Therapeutics Co.,Ltd. | 5.33 Billion KRW | 79.978% |
| LegoChem Biosciences, Inc. | 196.83 Million KRW | -442.771% |
| PharmaResearch Co., Ltd. | 50.23 Billion KRW | 97.873% |
| SillaJen, Inc. | 1.21 Billion KRW | 11.897% |
| JETEMA, Co., Ltd. | 12.74 Billion KRW | 91.615% |
| OliX Pharmaceuticals,Inc | 468.4 Million KRW | -128.082% |
| Genomictree Inc. | 496.53 Million KRW | -115.164% |
| MedPacto, Inc. | 620.00 KRW | -172315902.581% |
| D&D Pharmatech | 3.45 Billion KRW | 69.035% |
| EASY BIO,Inc. | 25.93 Billion KRW | 95.881% |
| GI Innovation, Inc. | - KRW | -Infinity% |